Pharming Group NV (PHAR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Pharming Group NV, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Pharming Group NV (PHAR) has returned -5.83% so far this year and 98.90% over the past 12 months.

Based on dividend-adjusted daily data since Dec 23, 2020, PHAR's average daily return is +0.09%, while the average monthly return is +0.89%. At this rate, your investment would double in approximately 6.5 years.

Historically, 42% of months were positive and 58% were negative. The best month was Aug 2022 with a return of +59.0%, while the worst month was Feb 2026 at -20.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, PHAR closed higher 45% of trading days. The best single day was Mar 24, 2023 with a return of +32.7%, while the worst single day was May 11, 2023 at -20.4%.

Pharming Group NV has an annualized alpha of 17.14%, beta of 0.57, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since December 24, 2020.

• This stock participated in 23.36% of S&P 500 Index downside but only 9.56% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.57 may look defensive, but with R² of 0.02 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PHAR ranks 82 for risk / return — in the top 82% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Pharming Group NV (PHAR) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Pharming Group NV. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Pharming Group NV was 60.45%, occurring on Jun 16, 2022. Recovery took 853 trading sessions.

The current Pharming Group NV drawdown is 21.44%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Pharming Group NV over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Pharming Group NV is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.